Investigational New Drugs

, Volume 31, Issue 4, pp 974–985

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

  • Sunil Sharma
  • Joachim Beck
  • Monica Mita
  • Sofia Paul
  • Margaret M. Woo
  • Margaret Squier
  • Brian Gadbaw
  • H. Miles Prince
PHASE I STUDIES

DOI: 10.1007/s10637-013-9930-2

Cite this article as:
Sharma, S., Beck, J., Mita, M. et al. Invest New Drugs (2013) 31: 974. doi:10.1007/s10637-013-9930-2
  • 356 Downloads

Summary

Purpose Panobinostat, a pan-deacetylase inhibitor, is a promising anti-cancer agent that increases acetylation of proteins associated with growth and survival pathways of malignant cells. The primary objective of this phase I dose-escalation study was to determine the maximum tolerated dose (MTD) of intravenous (i.v.) panobinostat administered on different dosing schedules in patients with advanced solid tumors or lymphoma. Secondary objective was to characterize safety and tolerability, pharmacokinetic profiles, and activities of the i.v. formulation. Methods i.v. panobinostat was administered at escalating doses on a daily (days 1–3 and 8–10 of a 21-day cycle; days 1–3 and 15–17 of a 28-day cycle) or weekly (days 1, 8, and 15 of a 28-day cycle; days 1 and 8 of a 21-day cycle) schedule, and safety and tolerability were monitored. Serial blood samples were collected following dosing for pharmacokinetic and pharmacodynamic analyses. Results The MTD for the daily administration schedule was 7.2 g/m2, whereas the MTD for the weekly schedule was 20.0 mg/m2. In addition to fatigue and cardiac arrhythmias, including prolonged QTcF, DLTs associated with the study drug were principally due to myelosuppressive effects. Maximum concentrations and bioavailability of i.v. panobinostat increased dose-proportionally across all doses evaluated. Conclusions Based on the results of this study and others, the i.v. formulation of panobinostat was well tolerated in many patients, but concerns remain regarding its potential suitability outside the study setting due to potential electrocardiogram abnormalities. Therefore, further development will focus on the panobinostat oral formulation.

Keywords

PanobinostatDACDACiCancer

Supplementary material

10637_2013_9930_MOESM1_ESM.docx (16 kb)
ESM 1(DOCX 16 kb)

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sunil Sharma
    • 1
  • Joachim Beck
    • 2
  • Monica Mita
    • 3
  • Sofia Paul
    • 4
  • Margaret M. Woo
    • 4
  • Margaret Squier
    • 4
  • Brian Gadbaw
    • 4
  • H. Miles Prince
    • 5
  1. 1.Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUSA
  2. 2.University of MainzMainzGermany
  3. 3.Cedars-Sinai Medical CenterLos AngelesUSA
  4. 4.Novartis Pharmaceuticals CorporationEast HanoverUSA
  5. 5.Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of OncologyThe University of MelbourneMelbourneAustralia